Search
00
GBAF Logo
trophy
Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

Subscribe to our newsletter

Get the latest news and updates from our team.

Global Banking & Finance Review®

Global Banking & Finance Review® - Subscribe to our newsletter

Company

    GBAF Logo
    • About Us
    • Profile
    • Privacy & Cookie Policy
    • Terms of Use
    • Contact Us
    • Advertising
    • Submit Post
    • Latest News
    • Research Reports
    • Press Release
    • Awards▾
      • About the Awards
      • Awards TimeTable
      • Submit Nominations
      • Testimonials
      • Media Room
      • Award Winners
      • FAQ
    • Magazines▾
      • Global Banking & Finance Review Magazine Issue 79
      • Global Banking & Finance Review Magazine Issue 78
      • Global Banking & Finance Review Magazine Issue 77
      • Global Banking & Finance Review Magazine Issue 76
      • Global Banking & Finance Review Magazine Issue 75
      • Global Banking & Finance Review Magazine Issue 73
      • Global Banking & Finance Review Magazine Issue 71
      • Global Banking & Finance Review Magazine Issue 70
      • Global Banking & Finance Review Magazine Issue 69
      • Global Banking & Finance Review Magazine Issue 66
    Top StoriesInterviewsBusinessFinanceBankingTechnologyInvestingTradingVideosAwardsMagazinesHeadlinesTrends

    Global Banking & Finance Review® is a leading financial portal and online magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management.
    Copyright © 2010-2026 GBAF Publications Ltd - All Rights Reserved. | Sitemap | Tags | Developed By eCorpIT

    Editorial & Advertiser disclosure

    Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

    Home > Finance > Wegovy, Mounjaro sales in India double on month in July
    Finance

    Wegovy, Mounjaro sales in India double on month in July

    Published by Global Banking & Finance Review®

    Posted on August 7, 2025

    2 min read

    Last updated: January 22, 2026

    Wegovy, Mounjaro sales in India double on month in July - Finance news and analysis from Global Banking & Finance Review
    Why waste money on news and opinion when you can access them for free?

    Take advantage of our newsletter subscription and stay informed on the go!

    Subscribe

    Tags:innovationresearchhealthcare

    Quick Summary

    Wegovy and Mounjaro sales in India doubled in July, reflecting increased demand for anti-obesity drugs. Wegovy launched in June, while Mounjaro's sales have surged since March.

    Table of Contents

    • Sales Growth of Anti-Obesity Drugs in India
    • Wegovy Sales Performance
    • Mounjaro Sales Surge
    • Market Dynamics and Competition

    Wegovy, Mounjaro sales in India double on month in July

    Sales Growth of Anti-Obesity Drugs in India

    By Rishika Sadam and Kashish Tandon

    Wegovy Sales Performance

    HYDERABAD (Reuters) -Sales of Danish drugmaker Novo Nordisk's Wegovy and U.S. rival Eli Lilly's Mounjaro in India doubled in July from a month earlier, data from research firm Pharmarack showed on Thursday.

    Mounjaro Sales Surge

    Demand for the blockbuster anti-obesity drugs, which help control blood sugar and slow digestion, has been on an upswing in the world's most populous nation.

    Market Dynamics and Competition

    Sales of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data showed.

    Mounjaro sales also doubled month-on-month to 157,000 units or 470 million rupees.

    "Though Wegovy has a strong prescriber base because of Rybelsus, substantial promotion may be needed to reach the Mounjaro patient base for the injectable market," Pharmarack's Vice President (Commercial) Sheetal Sapale said in a statement.

    In India, Novo has been selling oral semaglutide pills under the brand name Rybelsus since 2022 for type 2 diabetes.

    Mounjaro's sales have soared 15 times since March, when the drug was launched in India.

    ($1 = 87.6790 Indian rupees)

    (Reporting by Rishika Sadam and Kashish Tandon; Editing by Mrigank Dhaniwala)

    Key Takeaways

    • •Wegovy and Mounjaro sales in India doubled in July.
    • •Wegovy launched in India in June with strong growth.
    • •Mounjaro sales increased 15 times since March launch.
    • •Rising demand for anti-obesity drugs in India.
    • •Market competition between Novo Nordisk and Eli Lilly.

    Frequently Asked Questions about Wegovy, Mounjaro sales in India double on month in July

    1What was the sales increase for Wegovy in July?

    Sales of Wegovy more than doubled to 5,000 units or 70 million rupees in July.

    2How did Mounjaro's sales perform in July?

    Mounjaro sales also doubled month-on-month to 157,000 units or 470 million rupees.

    3What is the significance of Rybelsus in the Indian market?

    Rybelsus has created a strong prescriber base for Wegovy, which may help in its promotion.

    4When was Mounjaro launched in India?

    Mounjaro was launched in India in March, and its sales have soared 15 times since then.

    5What are Wegovy and Mounjaro used for?

    Both Wegovy and Mounjaro are anti-obesity drugs that help control blood sugar and slow digestion.

    More from Finance

    Explore more articles in the Finance category

    Image for Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Russia launches massive attack on Ukraine's energy system, Zelenskiy says
    Image for Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Russia launched 400 drones, 40 missiles to hit Ukraine's energy sector, Zelenskiy says
    Image for The Kyiv family, with its pets and pigs, defying Russia and the cold
    The Kyiv family, with its pets and pigs, defying Russia and the cold
    Image for Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Two Polish airports reopen after NATO jets activated over Russian strikes on Ukraine
    Image for French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    French miner Eramet's finance chief steps aside temporarily, days after CEO ouster
    Image for Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Ukraine's Zelenskiy calls for faster action on air defence, repairs to grid
    Image for Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Goldman Sachs teams up with Anthropic to automate banking tasks with AI agents, CNBC reports
    Image for Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Analysis-Hims' $49 weight-loss pill rattles investor case for cash-pay obesity market
    Image for Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Analysis-Glencore to focus on short-term disposals as Rio deal remains elusive
    Image for Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Belgium's Agomab Therapeutics valued at $716 million as shares fall in Nasdaq debut
    Image for Big Tech's quarter in four charts: AI splurge and cloud growth
    Big Tech's quarter in four charts: AI splurge and cloud growth
    Image for EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    EU hikes tariffs on Chinese ceramics to 79% to counter dumping 
    View All Finance Posts
    Previous Finance PostRussia and India talk up 'strategic partnership' after Trump tariff hike
    Next Finance PostUK's Morgan Advanced Materials plunges on profit warning